Modality
Degrader
MOA
TYK2i
Target
VEGF
Pathway
Autophagy
Narcolepsy
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
Jul 2020
→ Oct 2029
Phase 1Current
NCT03321647
2,553 pts·Narcolepsy
2020-07→2029-06·Active
NCT04324518
2,653 pts·Narcolepsy
2024-12→2029-10·Not yet recruiting
5,206 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-06-203.2y awayPh2 Data· Narcolepsy
2029-10-213.6y awayPh2 Data· Narcolepsy
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
P1/2
Not yet…
Catalysts
Ph2 Data
2029-06-20 · 3.2y away
Narcolepsy
Ph2 Data
2029-10-21 · 3.6y away
Narcolepsy
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03321647 | Phase 1/2 | Narcolepsy | Active | 2553 | HAM-D |
| NCT04324518 | Phase 1/2 | Narcolepsy | Not yet recr... | 2653 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF |